Izervay™ (avacincaptad pegol intravitreal solution)

Izervay (avacincaptad pegol) is covered only for geographic atrophy secondary to age‑related macular degeneration (FDA‑approved use) and is not supported for non‑FDA indications. Coverage requires the treated eye to have BCVA between 20/25 and 20/320, administration by or under an ophthalmologist, documentation of diagnosis and BCVA, and a plan for 2 mg (0.1 mL of 20 mg/mL) intravitreal injections once monthly per affected eye for up to 12 months.

"Izervay is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD)."

Sign up to see full coverage criteria, indications, and limitations.